Reply: Economic Impacts Associated With Recombinant Bovine Somatotropin (rBST) Use

Abstract

Losinger's criticism of our paper pertains to the following key points: the use of national estimates, the functional form employed, making multiple uses of the model, not considering all the costs, and the use of NAHMS data for economic analysis. We briefly address each one below.